Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KalVista Pharmaceuticals Inc
KALV | US
20.48
USD0.92
4.70%
KALV | US
About KalVista Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/07/2024
As of date
17/04/2026
Close
20.48
Open
19.97
High
20.80
Low
19.74
KalVista Pharmaceuticals Inc. a clinical stage pharmaceutical company discovers develops and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001 a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat which is initiation of the Phase 3 KONFIDENT trial as a potential oral on-demand therapy for HAE attacks; KVD824 an oral product candidate for the treatment of HAE; and Factor XIIa an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge Massachusetts.
View LessKALV | US
Risk
73.4
Sharpe
1.04
Luna's Score
57/100
Recommendation
Hold
Luna says (KALV | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
58.4%1 month
73.4%3 months
59.9%6 months
63.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.02
Debt to equity
0.04
Debt to assets
0.03
Ent. to EBITDA
-3.53
Ent. to rev.
76.33
PEG
-
Other Fundamentals
EBITDA
-154.72M
MarketCap
885.05M
MarketCap(USD)
885.05M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
30.70
Ret. on equity
-90.84
Short ratio
12.17
Short perc.
17.34
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.10
Range1M
6.21
Range3M
7.08
Volumes: Market Activity
Rel. volume
0.88
Price X volume
22.29M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.53 | - | Cheaper |
| Ent. to Revenue | 76.33 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.02 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 59.94 | - | Par |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 885.05M | - | Emerging |
